China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway
Over the last decade, China has become a key destination for oncology clinical trials, with Chinese sites increasingly incorporated within…
All articles by Miranda Mclaren
Miranda Mclaren
-
-
Central, local, or hybrid? Designing smarter depot strategies for clinical trials
The design of depot strategy has long been framed as a fundamental trade-off within the clinical trial supply chain. Sponsors…
-
Biomarkers in Nephrology Research: From Exploratory to Decision-Making Tools
While strategic use of biomarkers in clinical trials has traditionally been associated with oncology, the potential for growth across other…
-
Early Biomarkers as Predictors of Nephrology Trial Trajectory
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
-
How gene therapies are changing the Qualified Person role in the EU
For organisations outside Europe, the role of the Qualified Person (QP) is often unfamiliar. In the EU and UK, however,…
-
Q&A: How 3PLs are navigating the latest pharma trends
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same…
-
The Ovarian Cancer Opportunity: Overcoming Complexity in Global Studies
Each year in the US, more than 21,000 women will receive a new diagnosis of ovarian cancer according to the…
-
Trends in Renal Research: Nephrology’s Shift to Focus and Precision
Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained…
-
Tell us: Is hospital connectivity keeping up with the demands of modern care in 2026?
For years, healthcare organizations have focused on enabling clinical mobility by giving clinicians access to systems, communication tools, and patient…
-
Operational Lessons from Global Nephrology Trials
From novel drug targets for chronic kidney disease (CKD)[i] to advances in multifunctional drugs promising better efficacy, recent developments in…